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We also evaluated small and large shift scenarios of 7.8% and 20.2%, respectively. 
We calculated the incremental QALYs, costs, and cost-effectiveness ratio (ICER) in 
each scenario. RESULTS: The assay strategy was dominant in all scenarios evalu-
ated. In the 5-year and lifetime horizon analyses, the assay resulted in 0.02 and 0.04 
more QALYs and $780 and $730 less in costs, respectively. The small and large shift 
scenarios resulted 0.02 and 0.05 more QALYs, and $5 and $1,300 less in costs over 
a lifetime horizon, respectively. The ICER was most sensitive to the assay cost, the 
AS health state utility, and the proportion of low-risk patients receiving AS in usual 
care. CONCLUSIONS: Our results suggest that the 8-protein prognostic assay is 
potentially cost-effective vs. usual care in patients with Gleason 3+3 & 3+4 prostate 
cancer. Future studies will evaluate the impact of the assay on patient/physician 
treatment choices in real-world settings.
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OBJECTIVES: To perform a cost-effectiveness analysis of Panitumumab+FOLFOX vs 
Bevacizumab+FOLFOX as first-line treatment on RAS-WT mCRC patients from the 
Mexican public healthcare system perspective. METHODS: The evaluation was per-
formed using a Markov model that simulates a hypothetical cohort of patients over 
seven health-stages in two-week transition cycles. Progression-free survival (PFS) 
and overall survival (OS) were used as reported in the PEAK trial. Resource use was 
obtained from five oncologists at four public healthcare institutions. Costs include 
chemotherapy, follow-up, adverse events, metastasis resection, second-line treat-
ment, palliative care, and funeral costs. Mexican Social Security Institute costs were 
applied. Costs and benefits are discounted at 5% for a 10-year time line. Additionally, 
a cost-minimization vs Cetuximab was performed due to equivalence in OS described 
in the ASPECCT trial and similar values of PFS and OS reported in first line for compa-
rable populations. RESULTS: The total costs are $1,048,009.42 for Panitumumab (mean 
life of 3.47 years), and $872,201.70 for Bevacizumab (mean life of 2.80 years), with a 
mean cost-effectiveness ratio per month of OS of $25.173 and $25.932, respectively. 
The 10-month projection for anti-EGFR therapies reveals a total cost of $779,873.60 
for Panitumumab and $1,119,871.90 for Cetuximab, which represents savings of 
$339,998.30 (30.4%) per patient. CONCLUSIONS: Panitumumab as first-line treat-
ment improves the clinical parameters of RAS-WT mCRC patients and presents a 
mean cost-effectiveness ratio similar to Bevacizumab in this population. Regarding 
to Cetuximab, Panitumumab is a cost-saving strategy, with reduction in total costs of 
treatment and administration for public healthcare institutions in Mexico.
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OBJECTIVES: Colorectal cancer is the second cause of cancer-related mortal-
ity worldwide. In Brazil, the National Cancer Institute estimated the occurrence 
of 32,600 new colorectal cancer cases (15,070 cases in males and 17,530 cases in 
females) for 2014. Considering the disease impact and the recent findings of relevant 
clinical trials under new biomarkers’ evaluations in the RAS gene, we developed a 
cost-effectiveness analysis evaluating the use of cetuximab in combination with 
FOLFIRI (folinic acid, fluorouracil and irinotecan) compared to FOLFIRI alone for met-
astatic colorectal cancer (mCRC) in RAS wild-type patients, in the public health care 
system in Brazil. METHODS: To estimate the costs and outcomes of the treatments 
we designed a Markov model in which patients with mCRC were evaluated consider-
ing the natural course of the disease during a time horizon of 10 years. The outcomes 
were evaluated in terms of life year saved. Efficacy data was retrieved primarily from 
the CRYSTAL trial, recently evaluated in light of the new RAS biomarker. Only direct 
2014 medical costs were considered. Costs were obtained from the public database 
DATASUS. Costs and outcomes were discounted to present value at a 5% annual 
rate. RESULTS: In the comparison with cetuximab+FOLFIRI vs FOLFIRI, the incre-
mental effectiveness estimated was 0.7 life years, with an incremental cost of BRL 
46,007.34, representing a cost-effectiveness ratio of 66,090.91. Considering a GDP per 
capita of BRL 24,065.00, the ICER calculated could be considered cost-effective since 
it would fall under the threshold of 3 times the GDP per capita. CONCLUSIONS: 
Cetuximab+FOLFIRI has shown to be cost-effective in mCRC RAS wild-type patients, 
enabling a significant and clinically meaningful increase in survival supported by 
the new findings from the CRYSTAL trial in the RAS population subgroup.
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OBJECTIVES: To evaluate the cost-effectiveness of conventional Transarterial 
chemoembolization with Lipiodol (cTACE) compared to Drug-Eluting-Bead-
Chemoembolization (DEB TACE) in patients with hepatocellular carcinoma (HCC) from 
the Ministry of health perspective. METHODS: A decision tree model was developed 
based on the Egyptian clinical practice, and was derived from published sources. This 
decision analytical model was constructed to assess the costs and consequences 
associated with cTACE compared with DEB TACE. The clinical parameters were derived 
from a comparative study previously published. Direct medical costs were obtained 
from the Ministry of health hospitals in Egypt. Deterministic sensitivity analyses 
were conducted. No discounting was conducted. RESULTS: The total survival days of 
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OBJECTIVES: To analyze the cost-effectiveness of imatinib as first-line therapy from 
2016-2021 compared to physician’s choice of other approved second-generation 
tyrosine kinase inhibitors (TKIs) dasatinib or nilotinib in chronic myeloid leukemia 
in chronic-phase (CML-CP), once imatinb loses patent exclusivity. METHODS: A 
Markov model simulating “imatinib-first” compared to “physician choice” in treat-
ing CML-CP in 2016 through 5 years from the U.S. commercial payer perspective. 
In both approaches, if initial treatment fails, patients are switched to second-gen-
eration TKIs. Patients switch if they fail efficacy endpoints: 12-month complete 
cytogenetic response (CCyR); or 3-month early molecular response (EMR). Patients 
are then followed from switching through overall survival. They can also dete-
riorate to accelerated phase/blast crisis or death. The model assumes stabilized 
prices of second-generation TKIs, but adjusts the price of imatinib to be 100% of 
the branded price for first 6-months, 60-80% for the second 6-months and 10-30% 
thereafter based on patent expiration. For each drug, probabilities of treatment 
choice, switching and failure were meta-analyzed from published clinical trials. 
Quality-adjusted life years (QALYs) were based on US-societal health utilities. Direct 
medical costs per patient were calcated from Marketscan commercial claims (2011-
2012), including annual drug prices. 2013 U.S.-dollars and QALYs were discounted 
at 3%. Univariate and multivariate sensitivity analyses tested parameters with 
greatest impact on results. Findings were interpreted from a willingness-to-pay of 
$100,000/QALY. RESULTS: Based on a 12-month CCyR, imatinib-first ($270,772; 3.80 
QALYs) was cost-effective compared to physician choice ($361,935; 3.93 QALYs), an 
incremental cost-effectiveness ratio (ICER) of $701,000/QALY. The ICER based on 
3-month EMR was $470,000/QALY. Results were robust to uncertainty. The proba-
bilistic sensitivity analysis demonstrated that imatinib-first was cost-effective in 
99% of simulations. CONCLUSIONS: When imatinib loses patent protection in 2016 
in the U.S. and its price declines, it will be the cost-effective treatment strategy for 
CML-CP compared to dasatinib and nilotinib.
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OBJECTIVES: Patients with HER2-positive metastatic breast cancer (MBC) who 
receive Trastuzumab and/or taxanes often need treatment with different agents, 
such as Ado-trastuzumab emtansine (TDM-1) or a combination of Lapatinib and 
Capecitabine (L+C), when disease progresses. Although TDM-1 has better efficacy in 
improving survival, its high cost compared to L+C needs further economic evalua-
tion. This study aimed to assess the cost-effectiveness of TDM-1 compared to L+C in 
MBC patients from a U.S. payer’s perspective. METHODS: A Markov model depicting 
MBC progression for a total of 120 21-day treatment cycles (6.9 years) was devel-
oped. Clinical endpoints in the model included progression-free survival and overall 
survival. The model included the impact of disease progression and toxicity from 
cancer drugs. Cancer drug toxicities included were thrombocytopenia, neutropenia, 
hepatotoxicity, peripheral neuropathy, and pulmonary toxicity. Effectiveness inputs 
were derived from a Phase-III clinical trial comparing TDM-1 and L+C; cost and 
utility inputs from published literature and expert opinion. All cost inputs were 
expressed in 2014 U.S. dollars. The incremental cost-effectiveness ratio (ICER) was 
calculated using quality-adjusted life years (QALY) as the effectiveness measure. 
One-way sensitivity analyses were performed. RESULTS: Patients receiving TDM-1 
cost $241,109 with 1.88 QALYs gained over the 6.9 years, compared with $200,541 
and 1.56 QALYs in L+C group. The base-case ICER was $124,247/QALY. Compared 
to L+C, patients treated with TDM-1 had an expected 0.45 years longer survival 
and 0.31 years longer progression-free survival. The ICER varied from $70,270 to 
$178,223 per QALY when the TDM-1 cost changed from 80 to 120% of its current 
price. CONCLUSIONS: The determination of TDM-1 being cost-effective for MBC 
patients depends on the willingness-to-pay threshold used. Patients derived sig-
nificant life expectancy gains from TDM-1, leading to longer treatment with this 
costly agent.
PCN90
Cost-effeCtiveNess of A bioPsy-bAsed 8-ProteiN ProgNostiC AssAy 
to oPtimize treAtmeNt deCisioNs iN gleAsoN 3+3 ANd 3+4 ProstAte 
CANCer
Roth J.A.1, Ramsey S.1, Carlson J.J.2
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 2University of Washington, Seattle, 
WA, USA
OBJECTIVES: Clinico-pathologic factors alone are insufficient to predict the likeli-
hood of progression of Gleason 3+3 & 3+4 prostate cancer. Therefore, many patients 
receive treatment, despite having unaggressive tumors. A novel prognostic assay 
(ProMark™) that uses quantitative measurements of protein biomarkers has been 
validated to predict prostate cancer aggressiveness at the time of biopsy. Our objec-
tive was to evaluate the potential cost-effectiveness of using this 8-protein assay to 
inform treatment decisions. METHODS: We developed a Markov model to estimate 
quality-adjusted life-year (QALY) and cost outcomes for assay and usual care (NCCN 
guidelines) strategies over 5-year and lifetime horizons. The proportion of patients 
classified as low, intermediate, and high-risk for each strategy was derived from 
the assay’s validation study. Treatment distributions, costs, utilities, and mortality 
were derived from the peer-reviewed literature. In the base case, we assumed an 
increase in the use of active surveillance (AS) vs treatment of 14.5% (vs usual care). 
